Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.

Summary

Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain with intent to treat or currently treated with opioids. Exclusion criteria will include current cannabis use, severe medical illness or lacking in capacity to be involved in study. TC and TP will be prescribed for use TID in predefined dosages and quantities.

Timeline

Start

2023-01

Primary completion

2023-01

Completion

2023-01

Drugs

Indications